DuoGenic StemCells (ROCO:7607) Stock Based Compensation: NT$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7607 DuoGenic StemCells Corp ROCO:7607
23 GF Score
Price NT$12.85
GF Value NT$51.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is DuoGenic StemCells Stock Based Compensation?

DuoGenic StemCells ROCO:7607 -1.15% 23 Stock Based Compensation is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:7607 with a GF Score™ of 23/100 and a GF Value™ of NT$51.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

DuoGenic StemCells's Stock Based Compensation for the six months ended in Dec. 2025 was NT$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil.

DuoGenic StemCells Stock Based Compensation Related Terms

DuoGenic StemCells Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for DuoGenic StemCells's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells Stock Based Compensation Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:7607
23GF Score
DuoGenic StemCells Corp ROCO:7607
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DuoGenic StemCells Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

What does a Stock Based Compensation of NT$0.00 Mil mean?
DuoGenic StemCells (ROCO:7607) has a Stock Based Compensation of NT$0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DuoGenic StemCells and its competitors.
Is DuoGenic StemCells' Stock Based Compensation too high?
DuoGenic StemCells' current Stock Based Compensation is NT$0.00 Mil. Overall, DuoGenic StemCells has a GF Score™ of 23/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Stock Based Compensation compare to VRTX and REGN?
DuoGenic StemCells' Stock Based Compensation of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DuoGenic StemCells and its competitors. DuoGenic StemCells's current Stock Based Compensation is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$12.85 — trading 75% below its estimated fair value. The current Stock Based Compensation is NT$0.00 Mil. DuoGenic StemCells' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Stock Based Compensation is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?

Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued. The current stock price of NT$12.85 is trading 75% below its estimated GF Value™ of NT$51.35. GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.

Key valuation signals for ROCO:7607:

  • Stock Based Compensation: NT$0.00 Mil
  • GF Value™: NT$51.35 vs. price of NT$12.85 (75% below fair value)
  • GF Score™: 23/100 with 2 warning signs

No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DuoGenic StemCells Business Description

Address Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
23GF Score

Get the complete analysis for ROCO:7607

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.85
Price
NT$51.35
GF Value